Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province

Jalalabadi, Y. and Shirazi, A. and Ghavam-Nasiri, M. R. and Aledavood, S. and Sardari, D. and Memar, B. and Shahidsales, S. and Varshoeetabrizi, F. and Dehghan, P. and Vosughiniya, H. (2018) Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy in patients with esophageal cancer in Khorasan Province. Journal of Cancer Research and Therapeutics, 14 (3). pp. 509-515.

[img] Text
Evaluating the expression of cyclooxygenase-2 enzyme by immunohistochemistry in normal and tumoral tissue before and after neoadjuvant chemoradiotherapy.pdf

Download (1MB)

Abstract

Background: Esophageal cancer is the third most common cancer in Iran. Neoadjuvant chemoradiotherapy (NCRT) is the appropriate treatment for esophageal cancer. Aim: This study investigated the expression of cyclooxygenase (COX)-2 enzyme in normal and tumoral tissues before any treatment in patients with esophageal cancer, this study also assessed the effect of NCRT on the expression of COX-2 enzyme in normal and tumoral tissue in samples derived by surgery furthermore, and this study investigated the relationship between expression of COX-2 enzyme and the pathologic tumor regression grade (PTRG) patients. Materials and Methods: In this study, a total of 120 patients admitted to Omid Hospital, Imam Reza Hospitals, and Reza-Mashhad Medical Center, who were treated with NCRT, were recruited and the expression of the COX-2 enzyme in normal and tumoral tissues was assessed by immunohistochemistry before and after treatment by an expert pathologist between zero and 300. PTRG was determined by a pathologist after treatment. Results: The mean levels of COX-2 expression, obtained from tumoral and normal tissue baseline biopsy in patients, were 177.69 and 64.29, respectively, while in surgical specimen were 177.25 and 49.84, respectively. A significant association was found between PTRG of surgical specimen and COX-2 expression in normal tissue (baseline biopsy) at diagnosis (P = 0.034). Conclusions: The results indicated that expression of COX-2 in tumoral tissues exceeds the expression of COX-2 in normal tissue of the baseline biopsy. Patients with a high expression of COX-2 in baseline tumor biopsies had less response to treatment of pathology compared to patients with lower expression of COX-2 in baseline tumor biopsies. © 2017 Journal of Cancer Research and Therapeutics | Published by Wolters Kluwer - Medknow.

Item Type: Article
Additional Information: Cited By :1 Export Date: 16 February 2020 Correspondence Address: Shirazi, A.; Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad UniversityIran; email: shirazia@sina.tums.ac.ir
Uncontrolled Keywords: Celecoxib esophageal cancer neoadjuvant chemoradiotherapy pathologic tumor regression grade cisplatin cyclooxygenase 2 fluorouracil adjuvant chemoradiotherapy adjuvant therapy aged Article cancer regression continuous infusion controlled study esophageal squamous cell carcinoma esophagus biopsy esophagus carcinoma esophagus dysplasia female human human tissue immunohistochemistry major clinical study male multiple cycle treatment protein expression reverse transcription polymerase chain reaction Western blotting adult biopsy chemoradiotherapy drug effect epidemiology esophagus resection esophagus tumor gene expression regulation genetics Iran middle aged neoadjuvant therapy pathology treatment outcome Esophageal Neoplasms Esophagectomy Gene Expression Regulation, Neoplastic Humans
Subjects: WB Practice of Medicine
WI Digestive System
QU Biochemistry
QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 12 May 2020 04:12
Last Modified: 12 May 2020 04:12
URI: http://eprints.mums.ac.ir/id/eprint/17348

Actions (login required)

View Item View Item